These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35227862)

  • 21. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of anaphylaxis to YF-VAX® yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.
    McClenathan BM; Taylor JN; Housel LA; Ryan M
    J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38051650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yellow fever vaccination status and safety in hemodialysis patients.
    Facincani T; Guimarães MN; De Sousa Dos Santos S
    Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
    Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
    Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
    Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
    J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study.
    Koehl B; Aupiais C; Schinckel N; Mornand P; Odièvre MH; Niakate A; Brousse V; Ithier G; Missud F; Holvoet L; Benkerrou M; Sorge F; Faye A
    J Travel Med; 2021 Apr; 28(3):. PubMed ID: 33550421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of yellow fever vaccination in pregnancy: findings from a cohort of active duty US military women.
    Hall C; Khodr ZG; Chang RN; Bukowinski AT; Gumbs GR; Conlin AMS
    J Travel Med; 2020 Sep; 27(6):. PubMed ID: 32830852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acceptance of yellow fever vaccine in the older traveller: a cohort study.
    Ferrara P; Masuet-Aumatell C; Ramon-Torrell JM
    Acta Biomed; 2021 Sep; 92(4):e2021098. PubMed ID: 34487067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.
    Adrien N; Hyde TB; Gacic-Dobo M; Hombach J; Krishnaswamy A; Lambach P
    Vaccine; 2019 Jul; 37(32):4511-4517. PubMed ID: 31266670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccinations for international travellers travelling from Greece.
    Pavli A; Spilioti A; Lymperi I; Katerelos P; Maltezou HC
    Travel Med Infect Dis; 2013; 11(4):225-30. PubMed ID: 23433917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.
    Huber F; Ehrensperger B; Hatz C; Chappuis F; Bühler S; Eperon G
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 29394383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.